Searching for polycystic ovary syndrome in postmenopausal women: Evidence of a dose-effect association with prevalent cardiovascular disease

Menopause

Volumn 14, Issue 2, 2007, Pages 284-292

  Krentz, Andrew J ^a   Von Mühlen, Denise ^a   Barrett Connor, Elizabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular disease; Hyperandrogenism; Insulin resistance; Menopause; Polycystic ovary syndrome

Indexed keywords

AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BIOCHEMISTRY; BODY MASS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DOSE RESPONSE; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; HYPERANDROGENISM; INFERTILITY; INSULIN RESISTANCE; INTERVIEW; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MENSTRUATION; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PHENOTYPE; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; SPONTANEOUS ABORTION; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CALIFORNIA; CARDIOVASCULAR DISEASES; CHOLESTEROL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; POSTMENOPAUSE; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; TRIGLYCERIDES;

EID: 34247590999     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/GME.0b013e31802cc7ab     Document Type: Article

References (83)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
2. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401-419.
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749.
4. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
5. Guzick DS. Polycystic ovary syndrome. Obstet Gynecol 2004;103:181-193.
6. Talbott EO, Zborowskii JV, Boudraux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol 2004;56:27-39.
7. Kousta E, Tolis G, Franks S. Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences. Hormones (Athens) 2005;4:133-147.
8. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
9. Corbin RH, Futterweit W, Nestler JE, et al. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract 2005;11:126-134.
10. Steinbaum SR. The metabolic syndrome: an emerging health epidemic in women. Prog Cardiovasc Dis 2004;46:321-336.
11. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003;14:365-370.
12. Sam S, Legro RS, Essah PA, Apridonidze T, Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 2006;103:7030-7035.
13. Wild RA. Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 2002;186:35-43.
14. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;90:1929-1935.
15. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52:595-600.
16. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003;24:302-312.
17. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF II, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2562-2568.
18. Lakhani K, Hardiman P, Seifalian AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 2004;175:353-359.
19. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:1-17.
20. Guzick DS. Cardiovascular risk in PCOS. J Clin Endocrinol Metab 2004;89:3694-3695.
21. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-1587.
22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(Suppl):S5-S10.
23. Kritz-Silverstein D, Wingard DL, Barrett-Connor E. Hysterectomy status and life satisfaction in older women. J Womens Health Gend Based Med 2002;11:181-190.
24. Kley HK, Schlaghecke R, Kruskemper HL. Stability of steroids in plasma over a 10-year period. J Clin Chem Clin Biochem 1985;23:875-878.
25. Rosner W. A simplified method for the quantitative determination of testosterone-estradiol-binding globulin activity in human plasma. J Clin Endocrinol Metab 1972;34:983-988.
26. Tremblay RR, Dube JY. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception 1974;10:599-605.
27. Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2000;23:912-918.
28. Hales CN, Randle PJ. Immunoassay of insulin with insulin-antibody precipitate. Biochem J 1963;88:137-146.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
30. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
31. Lipid Research Clinics Program (US). Manual of Laboratory Operations, Lipid and Lipoprotein Analysis. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, 1974. Dhew Publication No. 75-628.
32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
33. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-58.
34. Rose G. The diagnosis of ischemic heart pain and claudication in field survey. Bull WHO 1962;27:645-658.
35. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Métodos de encuesta sobre enfermedades cardiovasculares. Geneva, Switzerland; World Health Organization, 1982. Monograph Series, no. 56.
36. Fraser IS, Kovacs G. Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:813-823.
37. van der Spuy ZM, Dyer SJ. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:755-771.
38. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
39. Wild RA, Grubb B, Hartz A, Van Nort JJ, Bachman W, Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 1990;54:255-259.
40. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32-35.
41. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:5454-5461.
42. Orio F Jr, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89:3696-3701.
43. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20:2414-2421.
44. Barrett-Connor E, Giardina EG, Gitt AK, Gudat U, Steinberg HO, Tschoepe D. Women and heart disease: the role of diabetes and hyperglycemia. Arch Intern Med 2004;164:934-942.
45. Nissen SE. Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am J Cardiol 2002;89:24B-31B.
46. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51:581-586.
47. Reich H. Issues surrounding surgical menopause. Indications and procedures. J Reprod Med 2001;46(3 Suppl):297-306.
48. Lewis CE, Groff JY, Herman CJ, McKeown RE, Wilcox LS. Overview of women's decision making regarding elective hysterectomy, oophorectomy, and hormone replacement therapy. J Womens Health Gend Based Med 2000;9(Suppl 2):S5-S14.
49. Lunde O, Djoseland O, Grottum P. Polycystic ovarian syndrome: a follow-up study on fertility and menstrual pattern in 149 patients 15-25 years after ovarian wedge resection. Hum Reprod 2001;16:1479-1485.
50. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604.
51. Edozien LC. Hysterectomy for benign conditions. BMJ 2005;330:1457-1458.
52. Arner P. Effects of testosterone on fat cell lipolysis. Species differences and possible role in polycystic ovarian syndrome. Biochimie 2005;87:39-43.
53. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000;73:724-729.
54. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217.
55. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000;85:645-651.
56. Moran C, Azziz R. The role of the adrenal cortex in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:63-75.
57. Vryonidou A, Papatheodorou A, Tavridou A, et al. Association of hyperandrogenemic and metabolic phenotype with carotid intimamedia thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:2740-2746.
58. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006;295:1288-1299.
59. Azziz R. PCOS: a diagnostic challenge. Reprod Biomed Online 2004;8:644-648.
60. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:671-683.
61. Jaffe RB. Editorial comment. Obstet Gynecol Surv 2005;60:37-39.
62. Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87:2013-2017.
63. Solomon CG, Hu FB, Dunaif A, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001;286:2421-2426.
64. Taponen S, Ahonkallio S, Martikainen H, et al. Prevalence of polycystic ovaries in women with self-reported symptoms of oligomenorrhoea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. Hum Reprod 2004;19:1083-1088.
65. Goodarzi MO, Quinones MJ, Azziz R, Rotter JI, Hsueh WA, Yang H. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance Fertil Steril 2005;84:766-769.
66. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428.
67. Chen MJ, Yang WS, Yang JH, Hsiao CK, Yang YS, Ho HN. Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS. Hum Reprod 2006;21:2266-2271.
68. Lord J, Wilkin T. Polycystic ovary syndrome and fat distribution: the central issue? Hum Fertil (Camb) 2002;5:67-71.
69. Salehi M, Bravo-Vera R, Sheikh A, Gouller A, Poretsky L. Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism 2004;53:358-376.
70. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-2600.
71. Taponen S, Martikainen H, Jarvelin MR, et al. Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab 2004;89:2114-2118.
72. Barrett-Connor E. Factors associated with the distribution of fasting plasma glucose in an adult community. Am J Epidemiol 1980;112:518-523.
73. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011.
74. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438.
75. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883-896.
76. Gambineri A, Pelusi C, Manicardi E, et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 2004;53:2353-2358.
77. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2003;81:19-25.
78. Adams JM, Taylor AE, Crowley WF Jr, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab 2004;89:4343-4350.
79. Kaltsas GA, Isidori AM, Besser GM, Grossman AB. Secondary forms of polycystic ovary syndrome. Trends Endocrinol Metab 2004;15:204-210.
80. Jacobs AK, Eckel RH. Evaluating and managing cardiovascular disease in women: understanding a woman's heart. Circulation 2005;111:383-384.
81. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
82. Matsuda M, De Fronzo RA. In vivo measurement of insulin sensitivity in humans. In: Draznin B, Rizza R, eds. Clinical Research in Diabetes and Obesity. Totowa, NJ: Humana Press, 1997:23-65.
83. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.